Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 15/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30225703 | 1.00 | KDM4E (0.56) | KDM4ELMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL23121513 | 0.85 | ANPEP (0.44) | KDM4ELMNAKMT2AALDH1A1DPP4 | |
| SCHEMBL74973 | 0.82 | L3MBTL1 (0.55) | KMT2AALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL31241181 | 0.82 | L3MBTL1 (0.55) | KMT2AALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL22635807 | 0.81 | KDM4E (0.51) | KDM4ELMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL4538988 | 0.80 | PTGS2 (0.39) | KDM4EKMT2AALDH1A1DPP4MAPT | |
| SCHEMBL2283350 | 0.79 | LMNA (0.51) | KDM4ELMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL30048865 | 0.79 | LMNA (0.51) | KDM4ELMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL18485418 | 0.78 | ALDH1A1 (0.56) | KDM4ELMNAKMT2AALDH1A1MEN1 | |
| Ethylene Glycol SCHEMBL8989789 | 0.78 | L3MBTL1 (0.51) | KDM4ELMNAKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411366-B1 | METHOD FOR THE PRODUCTION OF POMALIDOMIDE | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2022-11-23 | — | — | EP | disclosed |
| US-20190040037-A1 | METHOD FOR THE PRODUCTION OF POMALIDOMIDE | EGIS GYOGYSZERGYAR ZRT. (HU) | 2019-02-07 | — | — | US | disclosed |
| EP-3411366-A1 | METHOD FOR THE PRODUCTION OF POMALIDOMIDE | Egis Gyógyszergyár Zrt. (HU) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017134476-A1 | METHOD FOR THE PRODUCTION OF POMALIDOMIDE | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2017-08-10 | — | — | WO | disclosed |
| US-RE45685-E1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2015-09-29 | — | — | US | disclosed |
| EP-1228071-B8 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2263669-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2255801-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2012-02-08 | — | — | EP | disclosed |
| US-8030343-B2 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2011-10-04 | — | — | US | disclosed |
| EP-1698334-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2255801-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7678825-B2 | Pharmaceutically active isoindoline derivates | CELGENE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080221196-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION | 2008-09-11 | — | — | US | disclosed |
| EP-1228071-B1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1698334-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | MAN HON-WAH | 2004-07-29 | — | — | US | disclosed |
| US-6667316-B1 | Amido or imido functionality; tumor necrosis factor alpha, phosphodiesterases, matrix metalloproteases and angiogenesis inhibitors | CELGENE CORPORATION | 2003-12-23 | — | — | US | disclosed |
| EP-1228071-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1228071-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001034606-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221196-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | PDE3A, PDE2A, PDE5A | KDM4E 619/4885LMNA 2777/4885KMT2A 1298/4885 |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | PDE3A, PDE5A, PDE2A | KDM4E 771/4885LMNA 3128/4885KMT2A 1774/4885 |
| US-20190040037-A1 | METHOD FOR THE PRODUCTION OF POMALIDOMIDE | PM20D2, HSD17B14, FUT5 | KDM4E 2685/4885LMNA 4316/4885KMT2A 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.